Hyderabad,
India; 29th July 2020: Hetero, one of India’s leading generic pharmaceutical companies
and the world’s largest producer of antiretroviral drugs, today announces the
launch of generic Favipiravir in India under the brand name ‘Favivir.’
Hetero has been granted the manufacturing and
marketing approval for Favipiravir from the Drug Controller General of India
(DCGI).
Favivir is the second drug developed by
Hetero after Covifor (Remdesivir) used in the treatment of Covid-19. It is an
oral antiviral medication that has demonstrated positive clinical outcomes.
Favivir improves treatment accessibility to a
significant amount of Covid 19 patient population, which usually sustains mild
to moderate symptoms. Hetero’s Favivir is priced at Rs. 59 per tablet and is
marketed and distributed by Hetero Healthcare Limited. The product is available
from today at all retail medical outlets and hospital pharmacies across the
country and will be sold only on prescription. Backed by strong vertical
integration capabilities, the drug is being manufactured at our world-class
formulation facility in India, which has been approved by stringent global
regulatory authorities such as USFDA and the EU, among others.
Source: Heteroworld.com
Click Here - for Official Announcement
Join for Regular Job Updates in Whats App & Telegram...
Thank You for Visiting
More Updates Visit daily @ www.pharmawisdom.co.in
No comments:
Post a Comment